| Source | Code | Name | Case count | Share of cases (%) |
|---|---|---|---|---|
| REIMB | REIMB_KELA(319)_ICD10(L40) | Adalimumab, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, sekukinumab and ustekinumab (skin psoriasis), Psoriasis | 307 | |
| REIMB | REIMB_KELA(319)_ICD10(L400) | Adalimumab, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, sekukinumab and ustekinumab (skin psoriasis), Psoriasis vulgaris | 250 | |
| REIMB | REIMB_KELA(134)_ICD10(L400) | General erythroderma, Psoriasis vulgaris | 148 | |
| REIMB | REIMB_KELA(319)_ICD10(L405) | Adalimumab, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, sekukinumab and ustekinumab (skin psoriasis), Arthropathic psoriasis (M07.0-M07.3*, M09.0*) | 96 | |
| REIMB | REIMB_KELA(377)_ICD10(L40) | Apremilast and dimethyl fumarate (psoriasis), Psoriasis | 61 | |
| REIMB | REIMB_KELA(134)_ICD9(NA) | General erythroderma, Name not found | 46 | |
| REIMB | REIMB_KELA(377)_ICD10(L405) | Apremilast and dimethyl fumarate (psoriasis), Arthropathic psoriasis (M07.0-M07.3*, M09.0*) | 43 | |
| REIMB | REIMB_KELA(134)_ICD10(L26) | General erythroderma, Exfoliative dermatitis | 26 | |
| REIMB | REIMB_KELA(377)_ICD10(L400) | Apremilast and dimethyl fumarate (psoriasis), Psoriasis vulgaris | 21 | |
| REIMB | REIMB_KELA(134)_ICD8(NA) | General erythroderma, Name not found | 12 | |
| REIMB | REIMB_KELA(134)_ICD9(6961A) | General erythroderma, Psoriasis and similar disorders, Other psoriasis | 12 | |
| REIMB | REIMB_KELA(319)_ICD10(L408) | Adalimumab, brodalumab, certolizumab pegol, etanercept, guselkumab, infliximab, ixekizumab, risankizumab, sekukinumab and ustekinumab (skin psoriasis), Other psoriasis | 10 | |
| REIMB | REIMB_KELA(134)_ICD10(NA) | General erythroderma, Name not found | 5 |